top of page
Next-Generation Medicines for Patients with Epilepsy and Other Neurological Diseases

Developing Next-Generation Medicines for Patients with Neurological Disease

Avata Biosciences is a clinical stage pharmaceutical company combining synthetic cannabinoids with a novel formulation process to create medicines for underserved patient populations.

CANNABIDIOL (CBD)

MOVING BEYOND THE PLANT

NEXT-GENERATION PHARMACEUTICAL GRADE CANNABINOID MEDICINES

WATER SOLUBLE Formulations

SOLID DOSE Preparations

IMPROVED Bioavailability

SCALABLE Manufacturing to address large populations

 CANNABIDIOL (CBD)

OUR APPROACH

NEXT-GENERATION CANNABINOID MEDICINES

Proprietary process that turns a water insoluble API into water soluble powder

Water soluble powder can be manufactured into capsules

Oil, alcohol and THC free

Solid Dose Cannabidiol

Treating Disease Where Significant Unmet Need Exists...

Avata Biosciences Therapeutics Focus.png

In Partnership with Oxford University for the improvement of Mental Health

And Delivering on a Robust Pipeline

PROGRAM

INDICATION

DISCOVERY

PRECLINICAL

PHASE 1

PHASE 2

PHASE 3

AVAT-021

Capsule

AVAT-022

Aqueous Solution

AVAT-021*

Capsule

AVAT-031

Solid Dose

AVAT-041

Solid Dose

Adult Focal Epilepsy

Pediatric Focal Epilepsy

Schizophrenia

Opioid Sparing

Addiction

AVATA SAP-021 in Adult Focual Epilepsy.png
AVATA SAP-021 in schitzophrenia.png
Avata Opioid Sparing
Avata Metabolic Weight Gain
Avata Pipeline

*In Partnership with Oxford University for the improvement of Mental Health

Our Pipeline

OUR TEAM

Leaders in Cannabinoid Science, Medicine and Commercialization

Avata Bio Icon

Rupert Haynes

Chief Executive Officer

Dr. Andrew Saich

Chief Medical Officer

Rupert Haynes Avata Biosciences.jpg
Rupert Haynes Avata Biosciences.jpg

Rupert is a cofounder of Avata Biosciences and Chief Executive Officer. Before Avata, he led the strategic commercial development of GW Pharmaceuticals' cannabinoid portfolio in preparation for the commercial launch of Epidiolex®.

Dr. Andrew Saich Avata Biosciences.jpg
Dr. Andrew Saich Avata Biosciences.jpg

Andrew is a cofounder of Avata Biosciences and Chief Medical Officer. Prior to Avata, he created and led the GW Pharmaceuticals International Medical Organization preparing and supporting the launch of Epidiolex® and Sativex in Europe.

Dr Venkat Goskonda Avata Biosciences.jpg
Dr Venkat Goskonda Avata Biosciences.jpg

Venkat is an expert in cannabinoids and pharmaceutical formulations having developed prescription products from concept through to commercialization, with more than 22 years of experience in drug development.

Julian Bryson Avata Biosciences.jpg
Julian Bryson Avata Biosciences.jpg

Julian is a cofounder of Avata Biosciences and Executive Chairman. Prior to his current role, he founded infection control technology development pioneers Sterilox Technologies and PuriCore Plc.

Dr. Venkat Goskonda Ph.D.

Chief Scientific Officer

Julian Bryson

Executive Chairman

Grace Powell

Head of Regulatory Affairs

Grace Powell Avata Biosciences.jpg
Grace Powell Avata Biosciences.jpg

Grace leads Avata’s regulatory work, having previously supported the FDA filing for Epidiolex® in the US while at GW Pharmaceuticals Plc.

Dr. Chris Hayes Avata Biosciences.jpg
Dr. Chris Hayes Avata Biosciences.jpg

Chris leads Avata’s IP strategy. He was formerly Vice President & Global Head of IP at Jazz Pharmaceuticals and VP of IP at GW Pharmaceuticals Plc.

Dr. Chris Hayes

Head of Intellectual Property

Jim Gillespie

Program Director

Jim Gillespie Headshot.jpg
Jim Gillespie Headshot.jpg

Jim leads program management across Avata’s assets. He was the program leader for the global commercialization of Epidiolex® at GW Pharmaceuticals Plc. and commercial lead for the integration with Jazz Pharmaceuticals.

Dr. Emma Cheetham

Patent Portfolio Director

Emma Cheetham Headshot.jpeg
Emma Cheetham Headshot.jpeg

Emma leads Avata’s IP portfolio development, and was responsible for generating the patent portfolios for Epidiolex® at GW Pharmaceuticals Plc.

OUR TEAM

Scientific Advisors

Dr Johannes Roebers

Johannes is assisting Avata Biosciences in the development and implementation of a fully integrated CMC and manufacturing plan. Johannes has over 25 years of experience in R&D leadership, commercial scale manufacturing design, strategy development, engineering and regulatory affairs. 

Professor Finbar O'Callaghan

Finbar is a Professor of Pediatric Neuroscience at the Institute of Child Health, University College London. He is a consultant pediatric neurologist at Great Ormond Street Hospital in London and advises Avata Biosciences on evolving treatment pathways in epilepsy and clinical trial design. 

Professor Philip McGuire

Philip is a Professor of Psychiatry, Department of Psychiatry at the University of Oxford. He is advising Avata Biosciences on the clinical application of Avata’s clinical assets in psychiatric illness, initially schizophrenia.

Avata Bio Icon

MEDIA

LATEST NEWS

AND EVENTS

May 13, 2024

Avata Biosciences Emerges to Develop Solid Dose Cannabinoid Medicines for Epilepsy and other Neurological Diseases

December 19, 2023

Sapient Therapeutics Announces Positive Phase 1 Results in Part B of its Solid Dose Prescription CBD Study

November 21, 2023

Sapient Therapeutics Announces Positive Phase 1 Results in Part B of its Solid Dose Prescription CBD Study

1934 E Camelback Road, Ste 120-437

Phoenix AZ 85016

6 Stratton Street, Mayfair, London,
W1J 8LD

Level 7, 330 Collins Street Melbourne
VIC 3000

AVA-WEB103-November 2024

© 2024 Avata Biosciences Inc. All rights reserved.

bottom of page